Personalizing therapy for metastatic breast cancer

Expert Review of Anticancer Therapy

Volumn 9, Issue 9, 2009, Pages 1223-1226

  Morris, Patrick G ^a   Hudis, Clifford A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bevacizumab; Metastatic breast cancer; Neratinib; PARP inhibitor; Pertuzumab; Poly ADP ribose polymerase; Trastuzumab MCC DM1

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BSI 201; CAPECITABINE; CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; HEAT SHOCK PROTEIN 90 INHIBITOR; LAPATINIB; NERATINIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PACLITAXEL; PERTUZUMAB; TAXANE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB MCC DM1; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SYSTEMIC THERAPY; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; NEOPLASM METASTASIS; RECEPTOR, ERBB-2;

EID: 70350647430     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.89     Document Type: Conference Paper

References (19)

1. Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. N. Engl. J. Med. 357, 39-51 (2007).
2. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med. 355, 2733-2743 (2006). (Pubitemid 46021510)
3. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001). (Pubitemid 32222155)
4. + breast cancer (BC) Proc. Am. Soc. Clin. Oncol. (2008) (Abstract 1028).
5. Holden S, Beeram M, Krop I et al. A Phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients (pts) with advanced HER2+ breast cancer (BC). Proc. Am. Soc. Clin. Oncol. (2008) (Abstract 1029).
6. + metastatic breast cancer (MBC): final results. Proc. Am. Soc. Clin. Oncol. (2009) (Abstract 1017).
7. Gelmon KA, Fumoleau P, Verma S et al. Results of a Phase II trial of trastuzumab (H) and pertuzumab (P) in patients (pts) with HER2-positive metastatic breast cancer (MBC) who had progressed during trastuzumab therapy. Proc. Am. Soc. Clin. Oncol. (2008) (Abstract 1026).
8. Cortés J, Baselga J, Petrella T et al. Pertuzumab monotherapy following trastuzumab-based treatment: activity and tolerability in patients with advanced HER2 positive breast cancer. Proc. Am. Soc. Clin. Oncol. (2009) (Abstract 1022).
9. Modi S, Stopeck AT, Gordon MS et al. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a Phase I dose-escalation study. J. Clin. Oncol. 25, 5410-5417, (2007). (Pubitemid 350232217)
10. Swaby R, Blackwell K, Jiang Z et al. Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: a Phase I/II study. Proc. Am. Soc. Clin. Oncol (2009) (Abstract 1004).
11. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 357, 2666-2676 (2007).
12. Miles D, Chan A, Romieu G. Randomized, double-blind, placebo-controlled, Phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. Proc. Am. Soc. Clin. Oncol. 26, (2008) (Late breaking abstract 1011).
13. Robert NJ, Dieras V, Glaspy J et al. RIBBON-1: randomized, double-blind, placebo-controlled, Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol (2009) (Abstract 1005).
14. Miller KD, Chap LI, Holmes FA et al. Randomized Phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 23, 792-799 (2005).
15. Conlin AK, Hudis CA, Bach A et al. Randomized Phase II trial of nanoparticle albumin-bound paclitaxel in three dosing schedules with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. (2009) (Abstract 1006).
16. Tutt A, Robson M, Garber JE et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. Proc. Am. Soc. Clin. Oncol. (2009) (Abstract CRA501).
17. O'Shaughnessy J, Osborne C, Pippen J et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): results of a randomized Phase II trial. Proc. Am. Soc. Clin. Oncol. (2009) (Abstract 3).
18. A study to evaluate pertuzumab + trastuzumab + docetaxel vs. placebo + trastuzumab + docetaxel in previously untreated HER2-positive metastatic breast cancer http://clinicaltrials.gov/show/NCT00567190
19. Bevacizumab and paclitaxel, paclitaxel albumin-stabilized nanoparticle formulation, or ixabepilone in treating patients with locally recurrent, stage IIIB, or stage IV breast cancer http://clinicaltrials.gov/show/NCT00785291